Autolus Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 752

Employees

  • Stock Symbol
  • AUTL

Stock Symbol

  • Share Price
  • $0.91
  • (As of Friday Closing)

Autolus General Information

Description

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Contact Information

Website
www.autolus.com
Formerly Known As
Newincco 1311 Limited
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • The Mediaworks, 191 Wood Lane
  • White City
  • London W12 7FP
  • England, United Kingdom
+44 020
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • The Mediaworks, 191 Wood Lane
  • White City
  • London W12 7FP
  • England, United Kingdom
+44 020

Autolus Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Autolus Stock Performance

As of 20-Nov-2026, Autolus’s stock price is $0.91. Its current market cap is $242M with 266M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.91 $0.98 $0.90 - $2.58 $242M 266M 2.08M -$0.96

Autolus Financials Summary

As of 30-Sep-2026, Autolus has a trailing 12-month revenue of $137M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 398,237 228,047 20,548 916,533
Revenue 137,434 75,388 10,120 1,698
EBITDA (209,519) (258,052) (234,395) (170,240)
Net Income (256,132) (287,528) (220,662) (208,383)
Total Assets 523,059 589,068 782,725 375,381
Total Debt 147,873 71,387 52,629 52,967
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Autolus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial

Autolus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial

Autolus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the t
Biotechnology
London, United Kingdom
752 As of 2025

South San Francisco, CA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Autolus Competitors (78)

One of Autolus’s 78 competitors is Allogene Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Zelluna Formerly VC-backed Oslo, Norway
Kite Pharma Formerly VC-backed Santa Monica, CA
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
You’re viewing 5 of 78 competitors. Get the full list »

Autolus Patents

Autolus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202506058-D0 Method Pending 23-Apr-2025
GB-202506059-D0 Methods Pending 23-Apr-2025
WO-2026226711-A1 Methods Pending 23-Apr-2025
WO-2026224472-A1 Products and methods for treating autoimmune diseases Pending 23-Apr-2025
GB-202503656-D0 Method Pending 12-Mar-2025 A61K40/11
To view Autolus’s complete patent history, request access »

Autolus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Autolus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial

Autolus ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.74 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Autolus’s complete esg history, request access »

Autolus FAQs

  • When was Autolus founded?

    Autolus was founded in 2014.

  • Where is Autolus headquartered?

    Autolus is headquartered in London, United Kingdom.

  • What is the size of Autolus?

    Autolus has 752 total employees.

  • What industry is Autolus in?

    Autolus’s primary industry is Biotechnology.

  • Is Autolus a private or public company?

    Autolus is a Public company.

  • What is Autolus’s stock symbol?

    The ticker symbol for Autolus is AUTL.

  • What is the current stock price of Autolus?

    As of 20-Nov-2026 the stock price of Autolus is $0.91.

  • What is the current market cap of Autolus?

    The current market capitalization of Autolus is $242M.

  • What is Autolus’s current revenue?

    The trailing twelve month revenue for Autolus is $137M.

  • Who are Autolus’s competitors?

    Allogene Therapeutics, Adaptimmune Therapeutics, Zelluna, Kite Pharma, and Carisma Therapeutics are some of the 78 competitors of Autolus.

  • What is Autolus’s annual earnings per share (EPS)?

    Autolus’s EPS for 12 months was -$0.96.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process